All In Biotech

Drug Trial Radar · NCT06972849

Caffeine Citrate to Improve Neonatal Outcomes.

BabyCCINO: Caffeine Citrate to Improve Neonatal Outcomes. A Neonatal Domain Within PLATIPUS.

Last checked: Nov 20, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 3,900 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

3,900

Planned (sponsor's estimate)

Start

Oct 2025

Primary completion

Dec 2029

Study completion Dec 2050

Sponsor

Lead sponsor
University of MelbourneAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, up to 32 weeks
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial to learn what dose/s of caffeine citrate works to treat preterm born babies who have episodes where they stop breathing. It will also learn about the safety of different doses of caffeine citrate for the variety of preterm-born babies that are prescribed this. The main question it aims to answer is: Which dose is the optimal dose of caffeine citrate for very preterm babies to prevent short-term death and disease? Researchers will compare three different doses of caffeine citrate, which are already used in clinical practice to treat breathing stoppages in preterm babies, to see which dose works best. No placebo will be used. Participants will be given a 'loading' dose of caffeine citrate \<72 hours of life, and a smaller 'maintenance' dose once a day, for as long as the baby needs this. This trial will be undertaken as part of the PLATIPUS trial (NCT06461429).

Conditions

  • Apnea of Prematurity

Interventions

  • Caffeine citrateDrug

    Clinically indicated for apnea of prematurity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants who progress by at least one level higher on the PLATIPUS Ordinal Outcome ScaleTime frame: At any time prior to 42 weeks' postmenstrual age or first discharge home from hospital (whichever is earlier)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.